Bioxyne Increases Director Samuel Watson’s Equity Stake Through Performance Awards

Bioxyne Limited ( (AU:BXN) ) has shared an announcement.

Bioxyne Limited has reported a change in the interests of director Samuel Watson, reflecting additional equity-based incentives tied to performance outcomes and shareholder approvals. Watson’s direct holding in Bioxyne increased by 20 million ordinary shares, awarded as a result of achieving 2025 performance milestones, and his performance rights rose to 39 million following resolutions approved at the company’s annual general meeting on 26 November 2025. These changes, implemented at no cash consideration, further align the director’s interests with those of shareholders and underscore the company’s ongoing use of equity incentives to retain and motivate key leadership.

The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.

More about Bioxyne Limited

Bioxyne Limited is an Australian-listed company operating in the health and wellness sector. Through entities including Breathe International Limited and its subsidiary Zonetech Wellness Limited, the group focuses on wellness-related products and services, leveraging its corporate structure to expand its presence in consumer health markets.

Average Trading Volume: 2,263,434

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$92.21M

See more insights into BXN stock on TipRanks’ Stock Analysis page.